vimarsana.com

Latest Breaking News On - Joan shen - Page 2 : vimarsana.com

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesHong kongSan diegoEmilie wuAndrew zhuGigi fengJingwu zangEli lillyWeimin tangJielun zhuYifei zhuWei fuJoan shenJohn longPrnewswire the company nasdaqJiahui international cancer center

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

- New appointments as part of the Company s strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an.

United statesHong kongSan diegoEmilie wuAndrew zhuGigi fengJingwu zangEli lillyWeimin tangJielun zhuYifei zhuWei fuJoan shenJohn longCompany nasdaqCommercialization executive council

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesHong kongSan diegoEmilie wuAmitkumar mehtaJoan shenGigi fengJohn longPrnewswire the company nasdaqLymphoma programPiacente group incUniversity of alabama at birminghamExchange commissionAmerican society of hematologyOneal comprehensive cancer centerAmerican society

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization.

United statesHong kongSan diegoEmilie wuAmitkumar mehtaJoan shenGigi fengJohn longPrnewswire the company nasdaqLymphoma programPiacente group incUniversity of alabama at birminghamExchange commissionAmerican society of hematologyOneal comprehensive cancer centerAmerican society

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 - read this article along with other careers information, tips and advice on BioSpace

United statesHong kongSan diegoEmilie wuAmitkumar mehtaJoan shenGigi fengJohn longPrnewswire the company nasdaqLymphoma programPiacente group incUniversity of alabama at birminghamExchange commissionAmerican society of hematologyOneal comprehensive cancer centerAmerican society

vimarsana © 2020. All Rights Reserved.